Anita S. Chong to Isoantibodies
This is a "connection" page, showing publications Anita S. Chong has written about Isoantibodies.
Connection Strength
8.801
-
From bench to bedside: reversing established antibody responses and desensitization. Curr Opin Organ Transplant. 2022 10 01; 27(5):376-384.
Score: 0.800
-
Pregnancy-induced humoral sensitization overrides T cell tolerance to fetus-matched allografts in mice. J Clin Invest. 2021 01 04; 131(1).
Score: 0.717
-
Transplantation tolerance modifies donor-specific B cell fate to suppress de novo alloreactive B cells. J Clin Invest. 2020 07 01; 130(7):3453-3466.
Score: 0.692
-
Desensitization in the Era of Precision Medicine: Moving From the Bench to Bedside. Transplantation. 2019 08; 103(8):1574-1581.
Score: 0.650
-
Outstanding questions in transplantation: B cells, alloantibodies, and humoral rejection. Am J Transplant. 2019 08; 19(8):2155-2163.
Score: 0.636
-
New insights into the development of B cell responses: Implications for solid organ transplantation. Hum Immunol. 2019 Jun; 80(6):378-384.
Score: 0.612
-
Heterogeneity of memory B cells. Am J Transplant. 2018 04; 18(4):779-784.
Score: 0.587
-
From Pipe Dream to Donor-Specific PC Elimination: Novel Ways to Target Alloantibodies. Transplantation. 2016 11; 100(11):2238-2239.
Score: 0.537
-
Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig. Am J Transplant. 2013 Sep; 13(9):2280-92.
Score: 0.427
-
Making a B-line for transplantation tolerance. Am J Transplant. 2011 Mar; 11(3):420-1.
Score: 0.361
-
Alloantibodies prevent the induction of transplantation tolerance by enhancing alloreactive T cell priming. J Immunol. 2011 Jan 01; 186(1):214-21.
Score: 0.357
-
Memory alloreactive B cells and alloantibodies prevent anti-CD154-mediated allograft acceptance. J Immunol. 2009 Feb 01; 182(3):1314-24.
Score: 0.314
-
Long-term control of alloreactive B cell responses by the suppression of T cell help. J Immunol. 2008 May 01; 180(9):6077-84.
Score: 0.298
-
Mechanisms of organ transplant injury mediated by B cells and antibodies: Implications for antibody-mediated rejection. Am J Transplant. 2020 06; 20 Suppl 4:23-32.
Score: 0.172
-
Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report. Am J Transplant. 2020 10; 20(10):2652-2668.
Score: 0.172
-
Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group. Transplantation. 2020 05; 104(5):911-922.
Score: 0.171
-
B cells as antigen-presenting cells in transplantation rejection and tolerance. Cell Immunol. 2020 03; 349:104061.
Score: 0.168
-
Evolving Approaches in the Identification of Allograft-Reactive T and B Cells in Mice and Humans. Transplantation. 2017 11; 101(11):2671-2681.
Score: 0.144
-
Adoptive Transfer of Tracer-Alloreactive CD4+ T Cell Receptor Transgenic T Cells Alters the Endogenous Immune Response to an Allograft. Am J Transplant. 2016 10; 16(10):2842-2853.
Score: 0.130
-
Delayed Cytotoxic T Lymphocyte-Associated Protein 4-Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection. Am J Transplant. 2016 08; 16(8):2312-23.
Score: 0.129
-
Establishment of a global virtual laboratory for transplantation: a symposium report. Transplantation. 2015 Feb; 99(2):381-4.
Score: 0.119
-
Memory B cells in transplantation. Transplantation. 2015 Jan; 99(1):21-8.
Score: 0.118
-
AST Cutting Edge of Transplantation 2013 Meeting Report: a comprehensive look at B cells and antibodies in transplantation. Am J Transplant. 2014 Mar; 14(3):524-30.
Score: 0.111
-
Experimental models of B cell tolerance in transplantation. Semin Immunol. 2012 Apr; 24(2):77-85.
Score: 0.094
-
Sensitization in transplantation: Assessment of Risk 2022 Working Group Meeting Report. Am J Transplant. 2023 01; 23(1):133-149.
Score: 0.052
-
Allograft tolerance induced by intact active bone co-transplantation and anti-CD40L monoclonal antibody therapy. Transplantation. 2002 Aug 15; 74(3):345-54.
Score: 0.050
-
Intact active bone transplantation synergizes with anti-CD40 ligand therapy to induce B cell tolerance. J Immunol. 2002 May 15; 168(10):5352-8.
Score: 0.049
-
Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. Am J Transplant. 2020 12; 20(12):3620-3630.
Score: 0.043
-
Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients. Am J Transplant. 2020 10; 20(10):2675-2685.
Score: 0.043
-
Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation. 1994 Apr 27; 57(8):1223-31.
Score: 0.028
-
Differential immune response to carbohydrate epitopes on allo- and xenografts: implications for accommodation. Transplant Proc. 2000 Aug; 32(5):991-3.
Score: 0.011
-
Pharmacologically induced regression of chronic transplant rejection. Transplantation. 1995 Nov 27; 60(10):1065-72.
Score: 0.008